Oral dIuretics in Very Intensive Treatment, an Early Intervention in Outpatients With Heart Failure
Status:
Unknown status
Trial end date:
2019-10-15
Target enrollment:
Participant gender:
Summary
In the present study, consecutive patients, older than 18 years, of both genders will be
included. The diagnosis of reduced Heart Failure (HfrEF) according to: Clinical pattern,
laboratories and Cardiac imaging (ESC criteria). Treatment will be assigned in two groups:
Bumetanide and another group will be received Indapamide. Each group received maximum
tolerated dose for seven days with Clinical and labs evaluations will be every 48 hrs.
(Face-to-face and/or telephone visits). Serum and urinary labs, EKG´s, Echo will be
evaluated. Daily in-home register will made. Final points were: Mortality, Urinary failure,
Clinical Impairment, Hospital admissions, Oedema. (MUCHO). All patients will be followed for
30 days.